SSA
HOWL icon

Schonfeld Strategic Advisors’s Werewolf Therapeutics HOWL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-174,724
Closed -$374K – 2020
2023
Q3 		$374K Sell
174,724
-151,978
-47% -$419K ﹤0.01% 1283
2023
Q2 		$996K Buy
326,702
+253,284
+345% +$713K 0.01% 974
2023
Q1 		$191K Buy
+73,418
New +$219K ﹤0.01% 1555
2021
Q3 		– Sell
-11,300
Closed -$197K – 2279
2021
Q2 		$197K Buy
+11,300
New +$155K ﹤0.01% 1680

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Schonfeld Strategic Advisors's HOWL Position: Q4 2023 in Review

Schonfeld Strategic Advisors sold out of Werewolf Therapeutics (HOWL) in Q4 2023, closing a stake of 174,724 shares — an estimated $374K sold.

Schonfeld Strategic Advisors first reported a position in HOWL in Q2 2021 and held it in 4 quarters. The position peaked at $996K in Q2 2023. 41 funds tracked by Wall St. Rank hold HOWL as of Q4 2023.

  • Schonfeld Strategic Advisors reported no remaining Werewolf Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 174,724 Werewolf Therapeutics shares in Q4 2023, an estimated $374K.
  • Schonfeld Strategic Advisors first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Werewolf Therapeutics position peaked at $996K in Q2 2023.
  • 41 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.